Failure of long-term therapy with sodium valproate in Cushing’s disease

1997 ◽  
Vol 20 (7) ◽  
pp. 387-392 ◽  
Author(s):  
Annamaria Colao ◽  
R. Pivonello ◽  
F. S. Tripodi ◽  
F. Orio ◽  
D. Ferone ◽  
...  
Keyword(s):  
Sodium Valproate ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Term Therapy ◽  
Long Term Therapy

Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing’s disease

Pituitary ◽  
2020 ◽  
Author(s):  
Cédric Fontaine-Sylvestre ◽  
Laurent Létourneau-Guillon ◽  
Robert A. Moumdjian ◽  
France Berthelet ◽  
André Lacroix
Keyword(s):  
Tumor Progression ◽  
Cushing’S Disease ◽  
Cushing's Disease ◽  
Term Therapy ◽  
Long Term Therapy

Effect of Long-Term Therapy with Sodium Valproate on Nail and Serum Trace Element Status in Epileptic Children

2004 ◽  
Vol 102 (1-3) ◽  
pp. 001-010 ◽  
Author(s):  
Ferah Armutcu ◽  
Elif Ozerol ◽  
Ahmet Gurel ◽  
Mehmet Kanter ◽  
Huseyin Vural ◽  
...  
Keyword(s):  
Trace Element ◽  
Sodium Valproate ◽  
Term Therapy ◽  
Trace Element Status ◽  
Epileptic Children ◽  
Serum Trace Element ◽  
Long Term Therapy

scholarly journals Cabergoline monotherapy in the long-term treatment of Cushing's disease

2010 ◽  
Vol 163 (5) ◽  
pp. 709-716 ◽  
Author(s):  
Ariane Godbout ◽  
Marcos Manavela ◽  
Karina Danilowicz ◽  
Hugues Beauregard ◽  
Oscar Domingo Bruno ◽  
...  
Keyword(s):  
Partial Response ◽  
Cushing’S Disease ◽  
Complete Response ◽  
Cushing's Disease ◽  
Term Therapy ◽  
Dopamine Receptor Agonist ◽  
Ectopic Acth ◽  
Free Cortisol ◽  
Long Term Treatment

BackgroundCabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. Identification of D2 receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's disease (CD).ObjectiveTo evaluate the long-term efficacy of cabergoline monotherapy in patients with CD.MethodsRetrospective analysis of non-randomized clinical therapy with cabergoline in 30 patients with CD treated in academic centers of Buenos Aires and Montreal. Cabergoline was initiated at 0.5–1.0 mg/week and adjusted up to a maximal dose of 6 mg/week based on urinary free cortisol (UFC) levels. Complete response to cabergoline was defined as a sustained normalization of UFC with at least two normal values measured at 1–3 months interval; partial response was defined as a decrease of UFC to <125% of the upper limit of normal, and treatment failure as UFC ≥125% of it.ResultsWithin 3–6 months, complete response was achieved in 11 patients (36.6%) and partial response in 4 patients (13.3%). After long-term therapy, nine patients (30%) remain with a complete response after a mean of 37 months (range from 12 to 60 months) with a mean dose of 2.1 mg/week of cabergoline. Two patients escaped after 2 and 5 years of complete response, but one patient transiently renormalized UFC after an increase in cabergoline dosage. No long-term response was maintained in four initial partial responders.ConclusionsCabergoline monotherapy can provide an effective long-term medical therapy for selected patients with CD, but requires close follow-up for dose adjustments.

The effect of long-term therapy with sodium valproate on oxidant/antioxidant status in epileptic children

2003 ◽  
Vol 32 (2) ◽  
pp. 115-122
Author(s):  
Elif Ozerol ◽  
Mehmet Aslan ◽  
Ecir Ali Cakmak ◽  
Mukaddes Gulec ◽  
Cengiz Yakinci ◽  
...  
Keyword(s):  
Sodium Valproate ◽  
Antioxidant Status ◽  
Term Therapy ◽  
Epileptic Children ◽  
Long Term Therapy

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia

2007 ◽  
Vol 40 (05) ◽  
Author(s):  
M Kungel ◽  
A Engelhardt ◽  
T Spevakné-Göröcs ◽  
M Ebrecht ◽  
C Werner ◽  
...  
Keyword(s):  
Surveillance Study ◽  
Term Therapy ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Long Term Therapy

Favorable long-term outcome of bilateral adrenalectomy in Cushing's disease

2014 ◽  
Author(s):  
Andrea Osswald ◽  
Eva Plomer ◽  
Christina Dimopoulou ◽  
Monika Milian ◽  
Rainer Blaser ◽  
...  
Keyword(s):  
Cushing’S Disease ◽  
Bilateral Adrenalectomy ◽  
Cushing's Disease ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document